Trial Profile

A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients With DSM-IV-TR Schizophrenia Followed by Open-Label Treatment With LY2140023.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pomaglumetad methionil (Primary) ; Aripiprazole
Indications Schizophrenia
Focus Pharmacodynamics; Registrational
Sponsors Denovo Biopharma; Eli Lilly and Company

Most Recent Events

05 Oct 2021 this study has been completed in Spain ( global end of the trial 2012-10-12 ) as per European Clinical Trials Database record
29 Aug 2012 Status changed from active, no longer recruiting to discontinued, according to an Eli Lilly media release.
15 May 2012 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com